follow us
disclaim warranti liabil
due number sourc inform servic acquisdata pti ltd servic obtain
inher hazard electron distribut may delay omiss inaccuraci inform
servic acquisdata pti ltd affili agent sale repres distributor licensor
warrant accuraci complet current merchant abil fit particular purpos
inform servic avail acquisdata pti ltd servic event acquisdata pti ltd
affili agent sale repres distributor licensor liabl license anyon els loss
injuri caus whole part conting beyond control procur compil interpret edit write
report deliv inform servic acquisdata pti ltd servic event acquisdata
pti ltd affili agent sale repres distributor licensor liabl license anyon els
decis made action taken license relianc upon inform servic consequenti
special similar damag even advis possibl damag license agre liabil
acquisdata pti ltd affili agent sale repres distributor licensor aris kind
legal claim whether contract tort otherwis way connect acquisdata pti ltd servic shall
exceed amount license paid use acquisdata pti ltd servic twelv month immedi
preced event give rise claim
first-quart world-wide sale billion increas exclud impact foreign
keytruda sale grew billion exclud impact foreign exchang sale grew
human health vaccin sale grew billion includ effect time exclud impact
compani activ antivir vaccin research
due impact compani lower full-year revenu rang billion
billion includ neg impact foreign exchang approxim
due impact compani lower full-year ep rang
lower full-year non-gaap ep rang includ neg impact
foreign exchang approxim
kenilworth -- busi -- merck nyse known msd outsid unit state
canada today announc financi result first quarter
challeng unpreced time qualiti first-quart perform reflect strong demand
portfolio innov product continu commerci clinic execut dedic resili
employe around world fundament busi remain strong said kenneth frazier
chairman chief execut offic merck global pandem pose challeng us includ
seriou threat health peopl busi economi around world without question industri
compani uniqu abil respons help world respond pandem work
collabor deliv solut coronaviru infect also maintain suppli medic import
product need
gener accept account principl earn per share assum dilut ep first
quarter non-gaap ep first quarter exclud acquisition- divestiture-rel
cost restructur cost
overal respons pandem merck focus protect safeti employe ensur
suppli medicin vaccin reach patient contribut scientif expertis develop
antivir vaccin approach support health care provid commun addit merck
work dilig continu effort discov develop new therapeut address societi unmet medic
need need persist despit pandem merck remain confid fundament underli demand
product prospect long-term growth though covid-rel disrupt patient abil access
health care provid caus near-term challeng
build experi antivir vaccin embark upon broad-bas develop
program merck team scientist research assess avail antivir
candid vaccin asset potenti impact respect vaccin merck
thought select proven platform past use gener vaccin desir qualiti
advanc discuss multipl group focus three differ viral vaccin platform detail
collabor announc necessari arrang final beyond search
vaccin also engag studi potenti antivir therapi could deploy rapidli
addit evalu compound laboratori identifi program laboratori
compani also engag rang research organ collabor effort acceler
develop medicin vaccin merck announc new research collabor
institut system biolog investig defin molecular mechan infect
identifi target medicin vaccin addit particip nih-l
acceler intervent vaccin activ consortium partnership aim
develop collabor framework priorit vaccin drug candid streamlin clinic trial
regulatori process and/or leverag asset among partner rapidli respond futur
busi
first quarter estim overal impact merck revenu immateri full-year
merck expect unfavor impact revenu approxim billion exclud impact foreign
exchang due compris approxim billion pharmaceut approxim
million anim health
first quarter within human health busi market asia pacif includ china saw neg impact
social distanc measur reduc access health care provid given earlier preval
viru wherea market particularli europ saw custom build inventori due concern suppli
abil access health care provid given social distanc measur
roughli two-third merck pharmaceut revenu compris physician-administ product
despit strong underli demand impact social distanc measur fewer well visit delay
elect surgeri due impact well priorit patient health care
provid result reduc administr mani human health product particular vaccin
well keytruda pembrolizumab implanon/nexplanon etonogestrel implant compani
anticip reduc demand physician-administ product pandemic-rel access measur remain
place addit declin medic visit elect surgeri also neg impact demand
certain product includ bridion sugammadex
anim health busi revenu posit impact approxim million first quarter
custom made advanc purchas secur suppli livestock product bravecto fluralan given
uncertainti relat expand social distanc measur compani expect reduc veterinari visit
decreas protein milk consumpt due restaur school closur neg impact busi
go forward merck also expect neg impact economi addit unfavor
effect anim health busi
oper expens posit impact first quarter approxim million primarili driven
lower promot sell cost delay clinic program spend due full-year
merck expect favor impact oper expens approxim million
compani expect reli government author determin oper return normal
cogniz durat spread sever outbreak critic determin purpos
full-year estim provid compani assum major neg impact
second quarter gradual return normal oper begin late second quarter extend
third quarter full return normal oper fourth quarter
merck financi strength strong balanc sheet allow continu capit alloc prioriti
includ invest research develop growth driver invest manufactur capac
expans pay dividend continu search value-enhanc busi develop howev given
prioriti current oper environ merck temporarili suspend share repurchas
merck updat guidanc take impact consider
driven steadfast commit patient make everi effort ensur patient affect area
enrol clinic trial abl continu treatment receiv appropri care monitor
condit fluid evolv local condit allow enrol patient on-going studi
start new studi
continu suppli medicin vaccin patient custom critic prioriti merck
date materi impact product suppli merck medicin vaccin
compani continu normal suppli level product includ keytruda gardasil
papillomaviru quadrival type vaccin recombin gardasil
papillomaviru vaccin recombin doubl product capac esmeron rocuronium
bromid muscl relax use intub certain countri outsid address surg market
demand due gener merck total suppli chain month length compani
current believ suppli medicin vaccin remain normal level pandem
facil employe
major merck manufactur plant clinic suppli site fulli oper laboratori
focus essenti oper implement step ensur busi continu mani market
includ offic laboratori remain open colleagu primarili work home
china offic laboratori plant open although office- laboratory-bas
colleagu continu work home mani market paus in-person interact health care
provid field-bas employe work home includ
addit effort ensur continu suppli medicin vaccin patient well
research effort aim find treatment vaccin merck engag sever effort part
address pandem activ support commun variou way includ
product donat person protect equip ppe donat fund relief organ includ
unit nation foundat solidar respons fund support world organ
 center diseas control prevent cdc foundat emerg respons fund
provid surgic face mask use part urgent effort address outbreak new york new
jersey merck mother compani global initi help end prevent matern death
compani provid fund help health system tackl better meet need pregnant women
follow deliveri recogn need addit health care profession includ doctor
nurs medic laboratori technician assist region viru spread announc
program enabl medic train employe volunt time aid commun maintain
base pay also taken number new step support patient may lost
job insur coverag crisi merck patient assist program continu ensur access
merck medicin cost elig patient number chang includ assess
patient real-tim financi situat provid addit assist enrol addit chang
 access assist program made due pandem continu
consid possibl way support commun well nation local relief effort
merck continu advanc develop program keytruda compani therapi lynparza
olaparib parp inhibitor co-develop co-commerci astrazeneca lenvima lenvatinib
mesyl oral avail tyrosin kinas inhibitor co-develop co-commerci eisai co ltd
eisai addit notabl develop follow
merck announc pivot phase trial investig keytruda combin
chemotherapi met one dual primari endpoint progression-fre surviv patient metastat
trial continu evalu dual primari endpoint overal surviv os
merck announc phase trial evalu keytruda treatment adult patient
relaps refractori classic hodgkin lymphoma chl met one dual primari endpoint per
pre-specifi analysi plan dual primari endpoint os formal test interim analysi
studi continu evalu os
merck announc phase trial evalu first-lin treatment keytruda patient
microsatellit instability-high msi-h mismatch repair defici dmmr unresect metastat
colorect cancer met one dual primari endpoint trial continu evalu dual
primari endpoint os
merck announc food drug administr fda accept grant prioriti review
new supplement biolog licens applic sbla keytruda seek acceler approv
monotherapi patient unresect metastat solid tumor tissu tumor mutat burden-high
tmb-h mutations/megabas progress follow prior treatment satisfactori
altern treatment option applic base part result phase trial
prescript drug user fee act pdufa date june
merck announc resubmiss sbla fda seek updat dose frequenc
keytruda includ mg dose infus minut everi six week addit current
approv dose mg everi three week sbla file across adult indic
keytruda includ monotherapi combin therapi
merck announc launch ontruz trastuzumab-dttb biosimilar refer biolog
medicin herceptin part develop commerci agreement samsung bioepi
merck astrazenca announc posit result phase profound trial evalu lynparza
men metastat castration-resist prostat cancer mcrpc homolog recombin repair
gene mutat hrrm whose diseas progress prior treatment new hormon agent nha
treatment enzalutamid abirateron result trial show statist signific clinic
meaning improv key secondari endpoint os lynparza versu enzalutamid abirateron
men mcrpc select atm gene mutat
merck astrazeneca announc fda approv kinas inhibitor koselugo selumetinib
treatment pediatr patient two year age older neurofibromatosi type
merck astrazeneca announc phase trial evalu cediranib investig oral
vascular endotheli growth factor receptor vegfr inhibitor combin lynparza versu platinum-bas
chemotherapi patient platinum-sensit relaps ovarian cancer meet primari endpoint
merck announc ervebo ebola zair vaccin live regist nation health author
six african countri democrat republ congo drc burundi ghana guinea rwanda zambia
approv addit countri africa anticip near futur
merck present result phase victoria studi evalu efficaci safeti vericiguat
investig solubl guanyl cyclas sgc stimulatori jointli develop bayer ag treat patient
heart failur reduc eject fraction follow worsen event result present
virtual american colleg cardiolog annual scientif session togeth world congress cardiolog
publish simultan new england journal medicin
merck announc pivot phase trial evalu efficaci safeti
gefapix investig oral administ select receptor antagonist treatment
refractori unexplain chronic cough met primari efficaci endpoint gefapix mg twice daili
treatment arm gefapix mg twice daili treatment arm meet primari efficaci endpoint
merck inc phase verti cv cardiovascular cv outcom trial steglatro ertugliflozin
oral sodium-glucos cotransport inhibitor achiev primari endpoint non-inferior major
advers cv event mace compar placebo patient type diabet mellitu establish
atherosclerot cv diseas mace defin time first event cv death non-fatal myocardi infarct
non-fatal stroke key secondari endpoint superior steglatro versu placebo time
composit cv death hospit heart failur cv death alon composit renal death
dialysis/transpl doubl serum creatinin baselin met pre-specifi hypothesi
statist test reduct hospit heart failur observ steglatro safeti
profil steglatro consist report previou studi detail result verti cv
schedul present june virtual american diabet associ scientif
merck announc organon co organon name new compani creat
intend spin-off women health trust legaci brand biosimilar busi remain fulli
commit spin-off transact believ track complet first half
merck announc today intent consolid new jersey campus singl new jersey
headquart locat rahway end
first-quart pharmaceut sale increas billion exclud unfavor effect foreign
exchang sale grew increas driven primarili growth oncolog vaccin partial off-set
on-going impact loss market exclus sever product
growth oncolog larg driven higher sale keytruda grew billion quarter
reflect strong momentum non-smal cell lung cancer nsclc indic well continu uptak
indic includ renal cell carcinoma rcc adjuv melanoma addit oncolog sale reflect
allianc revenu million relat lynparza million relat lenvima repres merck share
profit product sale net cost sale commerci cost
growth vaccin first quarter driven higher sale gardasil/gardasil reflect time
shipment approxim million china time public sector purchas approxim million
 higher demand china europ well price growth partial off-set
unfavor effect certain market particularli hong kong
growth vaccin also driven pneumovax pneumococc vaccin polyval vaccin help
prevent pneumococc diseas reflect higher demand europ primarili due
growth vaccin partial off-set lower sale pediatr vaccin varivax varicella viru vaccin
live vaccin help prevent chickenpox m-m-r ii measl mump rubella viru vaccin live
vaccin help prevent measl mump rubella primarili reflect lower demand time govern
tender latin america previous disclos merck expect full-year sale varivax lower
prior year due part time govern tender select latin american market full-year
 sale m-m-r ii lower prior year driven declin expect demand relat fewer
perform hospit acut care reflect higher demand global particularli bridion medicin
revers neuromuscular blockad induc rocuronium bromid vecuronium bromid adult
undergo surgeri although compani anticip demand neg affect reduct elect
surgeri due on-going launch prevymi letermovir medicin prophylaxi
prevent cytomegaloviru cmv infect diseas adult cmv-seroposit recipi allogen
pharmaceut sale growth quarter partial off-set on-going impact loss market
exclus includ nuvar etonogestrel/ethinyl estradiol vagin ring noxafil posaconazol emend
aprepit vytorin ezetimibe/simvastatin cubicin daptomycin remicad infliximab addit
declin sale januvia sitagliptin janumet sitagliptin metformin reflect continu price
pressur
anim sale total billion first quarter increas compar first
quarter exclud unfavor effect foreign exchang anim health sale grew growth
livestock product due product acquir prior year antelliq corpor acquisit
relat buy-in describ growth companion anim product driven larg demand
bravecto line product parasit control due part buy-in
gaap expens ep relat inform
gross margin first quarter compar first quarter increas
reflect favor product mix lower acquisition- divestiture-rel cost partial off-set unfavor
effect royalti manufactur varianc price pressur inventori write-off foreign exchang
sell gener administr expens billion first quarter increas
compar first quarter increas primarili reflect higher acquisition- divestiture-rel cost
includ cost relat compani plan spin-off organon partial off-set lower promot sell
administr cost due part pandem favor effect foreign exchang
research develop expens billion first quarter increas compar
first quarter increas primarili driven higher expens relat clinic develop
increas invest discoveri research earli drug develop higher licens cost partial off-set
program project delay less travel meet due pandem
incom expens net million expens first quarter compar million
expens first quarter primarili reflect incom invest equiti secur
compar loss lower impair charg partial off-set higher net interest expens
effect incom tax rate first quarter
gaap ep first quarter compar first quarter
non-gaap expens ep relat inform
non-gaap gross margin first quarter compar first quarter
decreas non-gaap gross margin reflect unfavor effect royalti manufactur varianc price
pressur inventori write-off foreign exchang partial off-set favor product mix
non-gaap sell gener administr expens billion first quarter decreas
compar first quarter decreas primarili reflect lower promot sell administr
cost due part pandem favor effect foreign exchang
non-gaap expens billion first quarter increas compar first quarter
increas primarili reflect higher expens relat clinic develop increas invest
discoveri research earli drug develop higher licens cost partial off-set program project
delay less travel meet due pandem
non-gaap incom expens net million expens first quarter compar
million expens first quarter primarili reflect higher net interest expens partial off-set
incom invest equiti secur compar loss
non-gaap effect incom tax rate first quarter
non-gaap ep first quarter compar first quarter
full-year updat guidanc merck provid includ impact pandem
neg impact foreign exchang expect partial off-set favor underli
busi strength compani expect reli government author determin oper
return normal cogniz durat spread sever outbreak critic determin
purpos full-year guidanc estim compani assum major neg
impact second quarter gradual return normal oper begin late second quarter
extend third quarter full return normal oper fourth quarter
merck lower full-year revenu rang billion billion includ neg
impact foreign exchang approxim mid-april exchang rate
merck lower full-year ep merck lower full-year non-
ep includ neg impact foreign exchang approxim
mid-april exchang rate non-gaap rang exclud acquisition- divestiture-rel cost cost
relat restructur program
acquisdata proud host leagu estim want opportun win free
subscript join acquisdata media telecommun leagu
global healthcar compani histori work make differ
make differ live peopl global innov medicin vaccin anim health
product commit premier research-intens biopharmaceut compani dedic
provid lead innov solut today futur
discov develop provid innov product servic save improv live around world
acquisdata date busi intellig report cover develop world
report vast archiv corpor document list compani around world
abbott global diversifi healthcar compani central purpos help peopl live healthiest possibl
live offer broad portfolio market-lead product align favor long-term healthcar trend
develop develop market build strong foundat year success abbott
pois deliv top-tier growth expand margin strong cash flow increas return sharehold
compani take toughest health challeng treat diseasesw aim make
remark impact peopl live highli focus research-driven biopharmaceut
today employe around world focu deliv transform medicin therapi
allergan plc nyse agn headquart dublin ireland global pharmaceut leader focus
develop manufactur commerci brand pharmaceut devic biolog surgic regen
medicin product patient around world
one world largest pharmaceut servic compani serv unit state
canada select global market focu pharmaceut suppli channel servic
pharmaceut manufactur healthcar provid compani servic solut rang nich premium
logist pharmaceut packag reimburs pharmaceut consult servic scale
posit healthcar industri valu bring channel help busi continu
commit unlock potenti biolog patient suffer seriou ill discov
develop manufactur deliv innov human therapeut approach begin use tool like
advanc human genet unravel complex diseas understand fundament human biolog
global science-l biopharmaceut busi innov medicin use million
time world around us chang burden diseas increas respond
increas focu growth innov patient-centr technolog digit
data advanc cutting-edg scienc
bausch health compani inc formerli valeant pharmaceut multi-national specialti pharmaceut
compani base laval canada bausch health focus improv peopl live health care
product deliv commit patient health care provid stakehold societi
build innov compani dedic advanc global health
baxter touch live million peopl around world everi day product therapi found
throughout hospit clinic er pharmaci icu well advanc patient
care home inc fortun american health care compani headquart
bristol-my squibb differenti compani led uniqu biopharma strategi leverag reach
resourc major pharma compani pair entrepreneuri spirit agil biotech firm work
everi day deliv innov medicin patient seriou life-threaten diseas
lilli found colonel eli lilli man commit creat high-qual medicin met real need
era unreli elixir peddl question charact charg gener employe
follow take find make better better
consid founder industri genentech member roch group deliv
promis biotechnolog year
genentech biotechnolog compani dedic pursu groundbreak scienc discov develop
medicin peopl seriou life-threaten diseas transform discoveri includ first
target antibodi cancer first medicin primari progress multipl sclerosi
science-l global healthcar compani special purpos help peopl feel better live
glaxosmithklin plc form result merger glaxo wellcom plc smithklin
beecham plc although histori trace back year london plough court pharmaci
johnson johnson believ good health foundat vibrant live thrive commun forward
progress that year aim keep peopl well everi age everi stage
life today world largest broadli base healthcar compani commit use reach
size good strive improv access afford creat healthier commun put healthi
mind bodi environ within reach everyon everywher
johnson johnson incorpor state new jersey
era unpreced complex healthcar patient care mani
organ deliv care need get much healthier
vision improv care everi set one product one partner one patient time
make happen everi day touch virtual everi aspect healthcar
novarti creat merger ciba-geigi sandoz novarti predecessor compani
trace root back year rich histori develop innov product
purpos reimagin medicin improv extend peopl live use innov scienc
technolog address societi challeng healthcar issu discov develop breakthrough
treatment find new way deliv mani peopl possibl also aim reward
invest money time idea compani
novo nordisk drive chang defeat diabet seriou chronic condit
novo nordisk global healthcar compani year innov leadership diabet care
heritag given us experi capabl also enabl us help peopl defeat seriou chronic
condit rare bleed disord growth hormon relat disord obes
headquart denmark novo nordisk employ approxim peopl countri market
product countri
start humbl begin year ago rural michigan today one largest
luther perrigo owner gener store apple-dri busi idea packag
distribut patent medicin household item countri store luther launch privat label concept
way enhanc custom loyalti addit cost offer imprint store name label
epsom salt sweet oil bay rum dozen wet dri good stock gener store
pfizer inc research-bas global biopharmaceut compani appli scienc global resourc
bring therapi peopl extend significantli improv live discoveri develop
manufactur healthcar product global portfolio includ medicin vaccin well mani
regeneron pharmaceut inc lead scienc technolog compani deliv life-
transform medicin seriou diseas inc compani headquart eastview
near tarrytown new york found physician-scientist year ago science-driven approach result
six fda-approv medicin numer product candid rang diseas includ asthma pain
cancer infecti diseas
field human health undergo profound scientif technolog chang point way major
therapeut innov patient
sanofi innov dna mission har new technolog new way work find
healthcar solut around world research develop strategi innov view
three angl scienc technolog digit
build strong global footprint size scale teva reaffirm commit place peopl
center strategi enabl mani possibl live better healthier day develop
produc market afford high qualiti gener drug well innov specialti pharmaceut
activ pharmaceut ingredi
biopharmaceut compani across america peopl go work everi day mission advanc
innov treatment cure make differ million patient live
commit ensur patient access medicin preserv strong economi support vibrant
research valuabl job also stand behind medicin creat valu provid
patient across health care system
new era medicin breakthrough scienc transform care approach treat
patient robust invest research develop biopharmaceut compani result
advanc discoveri unlik anyth weve seen applic genom develop person
medicin enabl physician tailor treatment uniqu need patient immunotherapi
har patient immun system fight variou condit includ cancer rare diseas
last decad alon biopharmaceut compani invest half trillion dollar invest
begin yield result open door entir new way tackl complex difficult
treat diseas time
progress see today revolution treat diseas save patient live improv qualiti life
public health across broad rang chronic rare condit new era medicin mani diseas
previous regard deadli manag potenti curabl today medicin
clinic develop around world across medicin pipelin clinic develop
potenti first-in-class treatment repres entir new approach treat diseas futur
never brighter research explor new frontier year ago may regard
scienc fiction transform patient live
new era medicin isnt good news healthit good news health care system societi
new innov medicin keep patient healthi hospit reduc need costli emerg
room visit hospit stay surgeri long-term care save money patient nation health
system look forward medicin best bet confront countri biggest health cost driver chronic
diseas condit cancer diabet heart diseas lead caus death disabl
unit state patient condit account health care spend iv continu
advanc treatment indispens address societi health econom challeng year
invest biopharmaceut innov improv save live also drive tremend contribut
american economi america role leader medic innov biopharmaceut
compani invest billion unit state industri america
industri support million job across countri employe across compani
go work everi day research develop new treatment cure patient occur even face
continu setback develop timelin extens cost high rate scientif
new medicin transform care patient fight debilit diseas like cancer hepat heart diseas
mani rare condit yet midst progress spend retail physician-administ medicin
continu repres overal health care spend next decad mani new medicin
revolution care patient yet spend medicin project continu remain small stabl
share health care spend occur market-bas system unit state promot
incent continu innov increas patient access need medicin leverag competit
control cost
 market highli competit robust competit brand gener andincreasinglybiosimilar
altern result medicin price fall dramat competit occur among brand name medicin
price fall even gener introduc market fact prescript fill patient
unit state gener typic cost fraction price initi brand medicin ix expect
dynam continu year ahead sinc billion brand sale project face gener
biosimilar competit
anoth reason current marketplac medicin success control cost health insur
pharmaci benefit manag pbm power sophist purchas use leverag negoti
discount rebat list price medicin today top three pbm manag
prescript fill unit state xi averag list price medicin given
rebat discount insur compani govern pbm entiti suppli chain often
requir larg rebat medicin cover xii fact evid suggest negoti discount rebat
price concess doubl sinc total billion
continu growth rebat discount keep prescript medicin price growth slowest rate
year doesnt feel way mani patient often negoti save make way
patient increasingli ask pay pocket innov medicin unlik care receiv
in-network hospit physician offic patient high deduct coinsur pay cost share base
list price medicin even though insur may receiv steep discount half commerci
insur patient out-of-pocket spend brand medicin base full list price xiv mean patient
high deduct health plan pay list price month medicin may pay hundredsor even
thousandsmor year insur pay medicin
insur increasingli expos patient list price medicin patient seen out-of-pocket cost
continu grow pharmaci commerci insur patient deduct seen out-of-pocket
cost brand medicin increas sinc
though rebat discount grown substanti health plan typic use portion negoti
rebat reduc premium enrolle rather directli lower cost patient face high cost-shar
due deduct coinsur creat system payer requir patient pay pocket
rebat save spread among health plan enrolle form lower premium ask sicker
patient subsid premium healthier enrolle exact opposit health insur suppos
chang need ensur billion negoti rebat discount price concess
use lower cost patient pharmaci counter research show high cost share associ
lower medic adher increas abandon rate put patient abil stay need
therapi risk share negoti discount could save certain commerci insur patient high deduct
coinsur annual increas premium less xx medicar
part polici ensur save negoti discount pass medicar beneficiari would also
improv afford senior strengthen competit incent part program exampl typic
medicar beneficiari diabet take five medicin could save year out-of-pocket cost
america biopharmaceut compani commit work policymak stakehold advanc
market-bas solut aim toward ensur patient access need treatment support continu
innov drive valu health care system address misalign suppli chain incent
statu quo work patient misalign incent health care system need chang
rebat price concess payer receiv biopharmaceut compani use lower
cost share patient pharmaci counter need improv afford predict
cost senior medicar part current limit out-of-pocket expens adopt out-
of-pocket cap medicar part would align benefit commerci insur market ensur
beneficiari face catastroph ill abl afford treatment provid patient
transpar medicin cost phrma member voluntarili direct patient link cost inform
direct-to-consum dtc televis advertis phrma also launch medicin assist tool
provid link referenc dtc televis advertis help patient connect financi assist
make medicin afford move toward health care system focus result measur
valu eye patient enabl privat sector develop new better way pay
medicin move toward value-driven health care system includ develop data provid
patient physician easy-to-us inform differ medicin work creation better measur
qualiti care take account patient feel reform allow new way insur pay
medicin advanc research method relat valu assess encompass outcom
matter patient famili import step toward goal
commit advanc market-bas reform promot competit modern drug discoveri
develop process get medicin approv effici ensur safeti need modern
drug discoveri develop process equip regul new technolog expertis keep
centuri scienc also need ensur time review approv gener biosimilar medicin
patient benefit less expens gener biosimilar medicin replac treatment follow expir
patent data protect addit unit state must continu incentiv medic innov
competit strong intellectu properti incent enforc within outsid unit
market-bas health care system work well control cost done help work even
better patient current system creat misalign incent pbm other suppli chain
favor medicin high list price rebat impact patient afford reform need
prevent pbm other suppli chain paid list price medicin instead fee base
valu servic provid wrong way address misalign incent greater govern
intervent marketplac negoti adopt harm practic countri restrict patient
access need medicin strengthen health care system must also address misalign profit incent
fuel hospit markup medicin provid consolid address misalign incent
present opportun reduc largest fastest contributor health care costshospit spend
pharmaceut research manufactur america phrma
acquisdata date busi intellig report cover develop world
report vast archiv corpor document list compani around world
